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Abstract
How LPS signals through toll-like receptors (TLRs) to induce NF-￿B and inflammatory cytokines 
in sepsis remains unclear. Major candidates for that process are MyD88 and Mal/TIRAP but their 
role needs to be further defined. Here, we have examined the role of MyD88 and Mal/TIRAP in 
primary human cells of non-myeloid and myeloid origin as physiologically relevant systems. We 
found that MyD88 and Mal/TIRAP are essential for LPS-induced I￿B￿ phosphorylation, NF-￿B 
activation and IL-6 or IL-8 production in fibroblasts and endothelial cells in a pathway that also 
requires IKK2. In contrast, in macrophages neither MyD88, Mal/TIRAP or IKK2 are required for 
NF-￿B activation or TNF￿, IL-6 or IL-8 production, although Mal/TIRAP is still involved in the 
production of IFN￿. Differential usage of TLRs may account for that, as in macrophages but not 
fibroblasts  or  endothelial  cells,  TLR4  is  expressed  in  high  levels  at  the  cell  surface,  and 
neutralization of TLR4 but not TLR2 blocks LPS signaling. These observations demonstrate for the 
first time the existence of two distinct pathways of LPS-induced NF-￿B activation and cytokine 
production  in  human  myeloid  and  non-myeloid  cells  defined  by  selective  utilization  of  TLR4, 
MyD88, Mal/TIRAP and IKK2, and reveal a layer of complexity not previously expected.
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Introduction
The  development  of  novel  therapies  for  sepsis  depends  on  the  understanding  of  the  basic 
mechanisms of the disease 
1. The principal active agent involved in the pathogenesis of sepsis is 
bacterial  lipopolysaccharide  (LPS),  an  essential  component  of  the  surface  of  gram-negative 
bacteria. LPS exerts its toxic effects by potently activating macrophages and endothelial cells, and 
inducing the expression of inflammatory cytokines such as TNF￿ and IL-6 
2-5. Thus, elucidating 
how LPS signals through cell surface receptors to induce inflammatory gene expression in humans 
is of major importance. 
Central to the recognition of LPS and also many other microbial products by the host is a family of 
transmembrane proteins that have leucine-rich repeats in their extracellular domains known as the 
toll-related receptors (TLR) 
6.  LPS interacts with a heterologous receptor that contains TLR4 
7,8 as 
well as CD14 
9,10 and MD2 
11-13. As CD14 is a glycosyl phosphatidylinositol-anchored protein and 
MD2 is on the cell surface, transduction of the LPS signal across the membrane is mediated by 
TLR4. TLR4, as all TLR family members, contains a cytoplasmic domain that is homologous to a 
cytoplasmic domain found in the IL-1 receptor known as the Toll/IL-1 receptor (IL-1R) homology 
(TIR) domain that is essential for downstream signaling 
14-16. 
The presence of the TIR domain in both TLR and IL-1 receptor family members suggested that 
these  receptors  use  an  identical  framework  of  signaling  molecules  to  exert  their  downstream 
effects. This was supported by subsequent studies in mouse and human cell lines. Thus IL-1R and 
TLR4  were  shown  to  engage  the  TIR-containing  cytosolic  adaptor  molecule  myeloid 
differentiation  protein  88  (MyD88)  through  homotypic  interactions 
17-19,  with  subsequent 
recruitment of IL-1-R-associated kinase (IRAK) and IRAK2, IRAK4 and TRAF6 
17,18,20,21. TRAF6 
is thought to subsequently activate NF-￿B either through the I￿B kinase (IKK) complex and the 
kinases TAB-1 and TAK-1 
22, or through ECSIT and MEKK-1  
23. 
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 4
The recent derivation of MyD88
-/- mice, however, challenged a universal role for MyD88 in LPS 
signaling. Although there was the expected complete ablation of IL-1 signaling, LPS still activated 
NF-￿B  although  the  ability  to  induce TNF￿  from  macrophages  was  lost 
24. In  addition,  LPS-
induced NF-￿B activation and up-regulation of co-stimulatory molecules in bone marrow-derived 
dendritic cells from these mice was not compromised 
25. To account for a MyD88-independent 
pathway  of  NF-￿B  activation,  a  novel  MyD88  homologue  termed  MyD88  adaptor-like  (Mal) 
protein 
26 or TIR domain-containing adaptor protein (TIRAP) 
27 was described. This was shown to 
act as an adaptor protein specifically involved in TLR4 but not other TLRs or IL-1R-induced NF-
￿B activation 
26,27. As Mal/TIRAP does not contain the death domain (DD) found in MyD88, this 
was proposed to induce an alternative signaling pathway that also involves PKR 
27 and leads to the 
induction of IFN￿ and IP-10 
28. 
Despite  the  above  studies,  the  relevance  of  MyD88  and  Mal/TIRAP  to  primary  human 
macrophages and other human primary cells has yet to be established. This is of key importance 
given the major role of LPS in the pathology of sepsis. In this study, we addressed the question of 
specificity of MyD88 and Mal/TIRAP in TLR signaling by examining the effect of wild-type (wt) 
and dominant negative (dn) forms of MyD88 and Mal/TIRAP on LPS and IL-1-induced NF-￿B 
activation and cytokine production in primary human cells of non-myeloid and myeloid origin. Our 
data show for the first time that the requirement for MyD88 and Mal/TIRAP in LPS signaling is 
cell type-dependent. Evidence is provided that in human synovial fibroblasts (SF) and umbilical 
vein endothelial cells (HUVEC), MyD88 and/or Mal/TIRAP are used as adaptor molecules for LPS 
signaling,  whereas  in  human  macrophages  LPS  can  employ  MyD88  and/or  Mal/TIRAP-
independent alternative pathways to activate NF-￿B and induce the expression of inflammatory 
cytokines. This conclusion of alternative pathways used by LPS is further supported by the cell-
type specific usage of TLR4 and IKK2. In contrast, Mal/TIRAP but not MyD88 is still employed in 
human macrophages for LPS-induced IFN￿ production. Our study demonstrates the complexity of 
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the signaling mechanisms used by LPS and reveals a specific role for MyD88 and Mal/TIRAP in 
NF-￿B activation in non-myeloid cells with important implications in terms of therapies targeted at 
blocking LPS and IL-1 signaling. 
Materials and Methods
Reagents. Human recombinant M-CSF, IL-1 and TNF￿ were gifts of Genetics Institute (USA), 
Roche (USA) and the Centre of Molecular and Macromolecular Studies (Poland), respectively. 
Mouse anti-human TLR4 (HTA125) and TLR2 antibodies (N-17) used for blocking studies were 
purchased from BioCarta (Germany) and Santacruz Biotechnology (USA), respectively. The mouse 
anti - human TLR4 antibody (HTA125) was also used for FACS. The mouse IgG1 and IgG2a isotope 
control antibodies and the secondary PE-conjugated anti-mouse Ig were purchased from Becton and 
Dickinson (UK).   
Isolation of cells and culture. Primary human synovial fibroblasts (SF), umbilical vein endothelial 
cells (HUVEC) and peripheral blood monocytes were isolated and cultured as previously described 
29-32. Macrophages were derived from monocytes after differentiation for 2-3 days with 100 ng/ml 
M-CSF. The mouse macrophage cell line RAW 264.7 was obtained from ATCC (UK) and mouse 
peritoneal macrophages were obtained from DBA/1 mice after intraperitoneal injection of starch.
Adenoviral vectors and their propagation. Recombinant, replication-deficient adenoviral vectors 
having no insert (Ad0), or encoding ￿-galactosidase (Ad￿-gal) and GFP (AdGFP) were provided 
from Drs A. Byrnes and M. Wood (Oxford, UK) and Quantum Biotech (Canada), respectively. The 
adenovirus  encoding  wild-type  or  dominant  negative  forms  of  MyD88  (AdMyD88wt  and 
AdMyD88dn)  and  Mal/TIRAP  (AdMalwt,  AdMalP125H  and  MalTIR)  were  generated  as 
previously  described 
33.  The  cDNAs  used  for  the  construction  of  MyD88  and  Mal/TIRAP 
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recombinant adenoviruses were gifts of Dr K. Burns (University of Lausanne, Switzerland) and Dr 
J. Sims (Amgen, Seattle, USA), respectively 
18,26. Finally, adenoviruses encoding dominant negative 
IKK2  (AdIKK2dn)  or  I￿B￿  were  kindly  donated  by  Dr  R.  de  Martin  (University  of  Vienna, 
Austria)  and  have  been previously  used  in  other  studies 
34-36.  All  viruses  produced are  E1/E3-
deleted, belong to the Ad5 serotype, and were grown as previously described 
37. 
Adenoviral infection of cells. HUVEC and macrophages were infected in serum-free medium with 
adenoviruses at a multiplicity of infection (m.o.i.) of 100. After 2 hours, the adenovirus-containing 
medium was removed and complete medium was added back. For passaged SF, a m.o.i. of 500 was 
used as these cells are more resistant to adenoviral infection 
38. For the mouse RAW macrophage 
cell line and primary peritoneal macrophages a m.o.i. of 500 was also used.
Western blotting and electrophoretic mobility shift assay (EMSA). Two days after infection SF, 
HUVEC or macrophages were stimulated with either vehicle control, 20 ng/ml TNF￿, 20 ng/ml IL-
1  or  10-100  ng/ml  LPS  for  45  minutes,  and  cytosolic  and  nuclear  extracts  were  prepared  as 
described 
39.  Cytosolic  proteins  were  subsequently  separated  by  SDS/PAGE  on  a  10%  (w/v) 
polyacrylamide gel and transferred onto a PVDF membrane for western blotting. Antibodies for 
IKK2 and I￿B￿ were purchased from Santa Cruz Biotechnology (USA). Nuclear extracts (10 µg) 
were examined for NF-￿B-DNA-binding activity by EMSA as previously described 
40.    
Analysis of cytokines. Cells were plated in 96- and 48-well tissue culture plates (Falcon, UK) and 
were  either  left  uninfected  or  infected  with  adenovirus.  Two  days  after  infection,  cells  were 
stimulated for 20h with 20 ng/ml TNF￿, 20 ng/ml IL-1 and various concentrations (0.01-1000 
ng/ml)  of  chloroform-extracted  E.  coli  LPS  (Sigma).  In  preliminary  experiments,  these 
concentrations  induced  maximal  cytokine  production  (data  not  shown).    Supernatants  were 
analyzed for TNF￿, IL-6 and IL-8 by ELISA (Pharmingen, UK). For TLR blocking experiments, 
cells were incubated with neutralizing anti-TLR2 or anti-TLR4 antibodies for 30 minutes prior to 
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addition of LPS. Absorbance was read on a spectrophotometric ELISA plate reader (Labsystems 
Multiscan Biochromic) and analyzed using the Ascent software (Thermo Labsystems, USA). In all 
cases, viability of the cells was not significantly affected over this time period when examined by 
the MTT assay (Sigma, Poole, UK) 
41.
Semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR). RNA was isolated 
using  the  Qiagen  RNA  Blood  isolation  kit  (Qiagen).  Total  RNA  was  reverse  transcribed  with 
Superscript  II  Rnase  H
-  reverse  transcriptase  (GIBCO-BRL,  Life  Technologies)  and  oligo(dT) 
primer.  For mouse IFN￿ amplification, the primers 5’-TGAGGACATCTCCCACGTCAA-3’ and 
5’-TCCAAGAAAGGACGAACATTCG-3’ were used. For human IFN￿ amplification, the primers 
5’-GCTACAACTTGCTTGGATTCC-3’  and  5’-CCTTAGGATTTCCACTCTGAC-3’  were  used. 
Amplification was performed in a Primus 96
plus PCR machine (MWC-Biotech) and the number of 
PCR cycles used was within the exponential phase of the reaction: i.e. where there is a log-linear 
relationship between the number of PCR cycles and the yield of PCR products 
42.
Results
Generation  of  adenoviral  constructs  expressing  MyD88  and  Mal/TIRAP. The  role  of  TIR 
expressing  adaptor  molecules  (MyD88,  Mal/TIRAP)  in  transducing  signals  from  TLR/IL-1R 
families has been studied in many systems but not primary human macrophages or other primary 
human cells. To remedy this, adenoviral constructs were generated expressing both wild type and 
dominant negative forms of MyD88 and Mal/TIRAP (Figure 1). The MyD88 dominant negative 
(AdMyD88dn) contained a 52 amino acid deletion as well as a Phe56Asn point mutation in the DD 
rendering it incapable of signaling as previously described 
18.  The Mal/TIRAP dominant negative 
cDNAs  used  were  previously  described  by  Fitzgerald  et  al 
26  and  consisted  of  a  Pro125His  
mutation that disrupts TIR function (AdMaldn) or a truncated molecule that has the TIR only 
(AdMalTIR).
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Fig. 1. Wild-type (wt) and dominant negative (dn) forms of MyD88 and Mal/TIRAP used in 
this study. MyD88wt contains an N-terminal DD and a C-terminal TIR domain whereas Malwt 
contains lacks a DD but still contains a C-terminal TIR domain. MyD88dn has a point mutation 
(Phe56Asn) and a 52 amino acid deletion spanning its DD that disrupt DD-DD interactions. Maldn 
has a point mutation (Pro125His) in its TIR domain that disrupts TIR domain interactions. MalTIR 
consists only of the Mal/TIRAP TIR domain.   
MyD88dn inhibits IL-1 but not LPS-induced NF-￿B activation and cytokine production in primary 
human macrophages. Infection of human macrophages with AdMyD88dn resulted in high levels of 
MyD88dn at m.o.i >50 (Figure 2A). Similar levels of expression were also seen with MyD88wt 
(data not shown). As expected, MyD88dn inhibited IL-1-induced I￿B￿ degradation and NF-￿B 
activation while it had no effect on TNF￿-induced activation of this transcription factor (figure 
2B). With respect to cytokine production, neither IL-1 or TNF￿ were able to induce the expression 
of TNF￿, IL-6 or IL-8 in human M-CSF differentiated macrophages (data not shown) suggesting 
that in addition to NF-￿B activation another signal is also required for this process. However in 
contrast to IL-1, MyD88dn had no effect on LPS function as shown by I￿B￿ degradation, NF-￿B 
activation and IRAK degradation (Figure 2, B-C), a consequence of the activation of this kinase, or 
MyD88wt 1
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Malwt 1 235
235 1 Maldn
70 235 MalTIR
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Death Domain TIR domain
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the production of the NF-￿B-dependent cytokines TNF￿, IL-6 (Figure 2, D-E) and IL-8 (data not 
shown). This lack of effect of MyD88dn was independent of the LPS concentration used (Figure2, 
D-E).
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Fig. 2. MyD88dn inhibits IL-1 but not LPS-induced NF-￿ ￿￿￿B activation or cytokine production 
(for LPS) in human macrophages. Macrophages were generated from peripheral blood monocytes 
after 2 days of culture with 100 ng/ml M-CSF. Marcophages were infected for 2h with adenoviruses 
overexpressing ￿-galactosidase or MyD88dn, in serum-free medium. Then cells were cultured in 
complete medium for another 2 days and treated with 20 ng/ml IL-1, 20 ng/ml TNF￿ or 0.01-100 
ng/ml LPS. For W.B. and EMSA, 10 ng/ml LPS was used. The expression of MyD88dn at different 
m.o.i. was examined by W.B. (A). After 45 min treatment, cytosolic and nuclear extracts were 
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collected  and  assayed  for  I￿B￿  by  W.B.  and  NF-￿B  DNA  binding  by  EMSA  (B).  After  20h 
treatment with LPS, cytosolic extracts were collected and assayed for IRAK degradation by W.B. 
(C).  After  20  h  treatment  with  LPS,  supernatants  from  uninfected  (white),  Ad￿-gal  (gray)  or 
AdMyD88dn (black) infected cells were collected and assayed by ELISA for TNF￿ (D) and IL-6 
(E). Mean cytokine production (±SD) of triplicate cultures is shown and is representative of five 
independent experiments from unrelated donors.
MyD88dn inhibits LPS-induced NF-￿B activation and cytokine production in RAW 264.7 cells but 
not primary mouse peritoneal macrophages. The data above on LPS did partially agree with data 
from MyD88
-/- mice suggesting a redundant role for MyD88 in LPS-induced NF-￿B activation but 
disagreed with data obtained in studies with the RAW 264.7 mouse macrophage cell line or the 
human THP-1 monocytic line 
19,26,27. Because, however, these studies used transfection rather than 
viral delivery, they were also repeated in RAW 264.7 cells with AdMyD88dn. Adenoviral gene 
transfer into RAW 264.7 gave high levels of expression of MyD88dn that resulted in inhibition of 
LPS-induced  TNF￿  production  (Figure  3,  A-B).  This  result  raised  the  issue  whether  the 
requirement for MyD88 in LPS signaling is an artifact of macrophage cell lines. When these studies 
were  repeated in  primary  peritoneal  macrophages, AdMyD88dn  also resulted  in  high  levels  of 
expression of MyD88dn (figure 3A) but this had no effect on LPS-induced TNF￿ production or 
NF-￿B activation (figure 3, C-D). In contrast to LPS, IL-1 did not induce NF-￿B activation (figure 
3D) or cytokine production (data not shown) above background levels in this cell type. 
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Fig. 3. MyD88dn inhibits LPS-induced TNF￿ ￿￿￿ production in mouse RAW cells but not in 
perinoneal macrophages. RAW cells and murine peritoneal macrophages were left uninfected 
(white)  or  infected  for  2h  with  adenoviruses  overexpressing  ￿-galactosidase  (gray),  MyD88wt 
(cross-hatched)  or  MyD88dn  (black),  in  serum-free  medium,  and  then  cultured  in  complete 
medium for another 1 day. Cells were lysed and cytosolic extracts collected and examined for the 
expression of MyD88 (A). RAW cells (B) and peritoneal macrophages (C) were treated with 1 
µg/ml LPS for a further 20 h, and supernatants were assayed by ELISA for TNF￿. Mean cytokine 
production  (±SD)  of  triplicate  cultures  is  shown  and  is  representative  of  three  independent 
experiments. Peritoneal macrophages were also treated with 1 µg/ml LPS or 20 ng/ml IL-1 for 45 
minutes and nuclear extracts collected and assayed for NF-￿B activation by EMSA (D). 
Maldn does not inhibit either IL-1 or LPS-induced NF-￿B activation and cytokine production in 
primary human macrophages. The ability of macrophages from MyD88
-/- mice to still induce NF-
￿B  in  response  to  LPS  suggested  the  existence  of  an  alternative  adaptor  molecule 
24.  The 
identification of Mal/TIRAP as a putative TLR4 specific TIR adaptor appeared to fulfill this role 
although studies were chiefly confined to cell lines 
26,27. Infection of human macrophages with 
AdMaldn produced high levels of expression of the protein over the endogenous levels (Figure 4A) 
and similar expression was seen with AdMalwt and AdMalTIR (data not shown). As expected, 
Maldn had no effect on IL-1-induced NF-￿B activation (Figure 4B), although there was also no 
effect  on  LPS-induced  I￿B￿  degradation,  NF-￿B  activation  (Figure  4B)  or  the  production  of 
cytokines, TNF￿ (Figure 4C), IL-6 (Figure 4D) or IL-8 (data not shown).  As for MyD88dn, the 
impotency of Maldn did not depend on the LPS concentration. 
To investigate whether either the failure to identify a functional role for Mal/TIRAP or 
MyD88 was due to redundancy between these molecules, studies were also performed using a 
combination of AdMaldn and AdMyd88dn but this again had no effect on LPS-induced TNF￿
production  (Figure  4E).  Although  the  majority  of  our  data  were  generated  with  AdMaldn, 
AdMalTIR was also used. Infection of macrophages with this virus again had no effect and rather 
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enhanced LPS-induced TNF￿ production (Figure 4E), although the reason for this effect is unclear. 
To confirm the effectiveness of Maldn as an inhibitor in primary human macrophages we also used 
AdMalwt. AdMalwt-induced IL-6 production in the absence of LPS stimulation was effectively 
blocked by the co-expression of Maldn (Figure 4F) indicating that the dominant negative can act as 
an inhibitor of Mal signaling in this cell type. 
As the data so far suggest that neither Mal/TIRAP  nor MyD88 are essential for LPS-
induced NF-￿B activation in macrophages, we decided to investigate whether Mal/TIRAP and 
MyD88 are involved in LPS-induced NF-￿B-independent pathways such as IFN￿ production. We 
found that AdMaldn and AdMalTIR but not AdMyD88dn inhibited LPS-induced IFN￿ mRNA 
expression  in  both  the  mouse  RAW  cell  line  and  primary  human  macrophages  (Figure  4G). 
However, this was not due to an obvious role of Mal/TIRAP on IRF3 activation as neither Maldn 
nor MalTIR inhibited LPS-induced IRF3 phosphorylation in RAW cells or human macrophages 
(data not shown), in agreement with previously published studies in Mal/TIRAP deficient mice that 
show that this adaptor is not required for this function 
43,44. How Maldn and MalTIR control the 
expression of IFN￿ in human macrophages is at present unclear.  
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Fig.  4.  Mal/TIRAP  is  dispensable  for  IL-1  or  LPS-induced  NF-￿ ￿￿￿B  activation  or  cytokine 
production in human macrophages. Human macrophages (A-G) or RAW cells (G) were infected 
for  2h  with  adenoviruses  expressing  ￿-galactosidase,  Malwt,  Maldn  or  MalTIR,  in  serum-free 
medium. Cells were cultured in complete medium for another 2 days and treated with 20 ng/ml IL-
1, 0.01-100 ng/ml LPS or 20 ng/ml TNF￿. For W.B. and EMSA, 10 ng/ml LPS was used. The 
expression of MyD88dn at different m.o.i. was examined by W.B. (A). After 45 min of treatment, 
cytosolic and nuclear extracts were collected and assayed for I￿B￿ expression by W.B. and NF-￿B 
DNA  binding  by  EMSA  (B).  After  20  h  of treatment  with  LPS,  supernatants  from  uninfected 
(white), Ad￿-gal (gray) or AdMaldn (black) infected cells were collected and assayed by ELISA for 
TNF￿ (C) and IL-6 (D). Combinations of AdMyD88dn with Ad￿-gal, AdMaldn or AdMalTIR 
were also used to infect human macrophages and their effect on TNF￿ production after treatment 
for 20h with 10 ng/ml LPS was examined (E). In addition, combinations of AdMalwt with Ad￿-gal 
or AdMaldn were also used to infect human macrophages and IL-6 production in the absence of 
further  treatment  was  examined  after  20h    (F).  Mean  cytokine  production  (±SD)  of  triplicate 
cultures is shown and is representative of five independent experiments from unrelated donors. 
Finally, total mRNA levels from RAW cells or human macrophages were extracted, quantified and 
equal amounts subjected to RT-PCR for IFN￿ and GAPDH amplification (G). A representative of 
three independent experiments is shown. 
MyD88  or  Mal/TIRAP  are  both  required  for  LPS-induced  NF-￿B  activation  and  cytokine 
production in human SF and HUVEC. LPS can stimulate a number of non-myeloid cells such as 
endothelial cells, fibroblasts and B-lymphocytes.  In general, signaling in non-myeloid cells by LPS 
has been restricted to cell lines often transfected with TLR4/CD14. Since our adenoviral constructs 
can effectively infect human umbilical vein endothelial cells (HUVEC) and primary synovial (SF) 
fibroblasts, we examined the role of MyD88 and Mal/TIRAP in these cells. Infection with the 
appropriate viral constructs resulted in the expression of wild-type or dominant negative versions 
of MyD88 and Mal/TIRAP in these cells (Figure 5A). Unlike macrophages, MyD88dn blocked 
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both IL-1 and LPS-induced IL-6 (Figure 5, B-C) or IL-8 (data not shown) production in HUVECs 
and  SF.  However,  Maldn  only  blocked  LPS-induced  signaling  in  these  cells  (Figure  5,  B-C), 
whereas TNF￿-induced cytokine production was unaffected by either construct (Figure 5, B-C). 
MyD88wt and Malwt, on the other hand, had no effect on any stimulus but their expression alone 
did  activate  NF-￿B  and  did  induce  IL-6  and  IL-8  production  (data  not  shown).  The  same 
differential effects of MyD88dn and Maldn in signaling were also observed at the transcription 
factor level where MyD88dn inhibited both LPS and IL-1-induced I￿B￿ degradation and NF-￿B 
activation in SF whereas Maldn only blocked LPS activity (Figure 5D). Similar data were obtained 
in HUVEC (data not shown). 
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Fig. 5. MyD88dn and Maldn block LPS induced NF-￿ ￿￿￿B activation and cytokine production in 
human SF and HUVEC. SF and HUVEC were infected with adenoviruses overexpressing ￿-
galactosidase, MyD88dn, Maldn or MalTIR in serum-free medium. Then cells were cultured in 
complete medium for another 1 day. (A) Cells were examined for the expression of MyD88dn and 
Maldn. SF (B) and HUVEC (C) were treated with 20 ng/ml IL-1, 0.01-100 ng/ml LPS or 20 ng/ml 
TNF￿ for 20 h, and supernatants from uninfected (white), Ad￿-gal (gray), AdMyD88dn (black), 
AdMaldn (cross-hatched) or AdMalTIR (checkered) infected cells assayed by ELISA for IL-6. 
Mean  cytokine  production  (±SD)  of  triplicate  cultures  is  shown  and  is  representative  of  five 
independent experiments from unrelated donors. SF were stimulated for 45 min with 20 ng/ml IL-
1, 100 ng/ml LPS or 20 ng/ml IL-1, cytosolic and nuclear extracts collected and then examined for 
I￿B￿ expression by W.B., and NF-￿B DNA binding by EMSA (D).
Overexpression of MalTIR domain blocks IL-1-induced cytokine production. The data with Maldn 
suggest that unlike MyD88, Mal/TIRAP has a selective role in LPS signaling as opposed to MyD88 
that is utilized by both LPS and IL-1.  However it must be noted that the nature of the dominant 
negative forms of MyD88 and Mal/TIRAP is different in so far as MyD88dn has a functioning TIR 
domain  whereas Maldn  does  not (see  Figure  1). Therefore  we repeated the studies  in  SF  and 
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HUVEC with the MalTIR construct. Infection with AdMalTIR inhibited LPS signaling as expected 
but in addition to that it also inhibited IL-1-induced IL-6 (Figure 5B).  These data would suggest 
that the TIR of Mal/TIRAP is capable of interacting with the IL-1 receptor when overexpressed. 
The implications of the differences that Maldn and MalTIR have on IL-1 function, and on our 
understanding of the signaling mechanisms of this cytokine will be addressed in the Discussion 
section 
Different requirements for TLR4 and IKK2 in LPS signaling in human macrophages and SF or 
HUVEC.  The  data  obtained  so  far  indicated  a  gross  difference  in  LPS  signaling  mechanisms 
between macrophages on one hand and SF and HUVECs on the other. This could not be accounted 
for higher LPS concentrations used with non-myeloid cells since Maldn and MyD88dn failed to 
inhibit macrophage activation at any concentration of endotoxin (Figure 2, D-E and Figure 4, C-D).  
An obvious putative reason for the data was that LPS is signaling through different receptors and/or 
pathways. As TLR4 is the most widely accepted, although not sole LPS-receptor, the ability of an 
anti - TLR4 neutralizing antibody to block LPS-induced cytokine production in SF, HUVEC and 
human macrophages was examined. In macrophages, an anti-TLR4 monoclonal antibody used at 
10 µg/ml prevented LPS-induced TNF￿ and IL-6 production at LPS concentrations of 0.1 ng-1 
ng/ml (Figure 6A) although the effect was lost at higher LPS concentrations (>10ng/ml, data not 
shown). This is likely to be due to increased competition of the higher LPS concentrations with the 
anti - TLR4 neutralizing antibody for the receptor. In contrast, in SF and HUVEC this antibody at 
concentrations of 10 µg/ml (Figure 6 B-C) and 50 µg/ml (data not shown) did not inhibit LPS-
induced IL-6 (Figure 6 B-C) or IL-8 production (data not shown), suggesting that LPS may not 
require cell  surface TLR4  to  signal in  these  cell  types. This  result  was  unlikely  to  be  due to 
contaminants present in the LPS preparation that induce signaling via TLR2 as shown previously 
45
as the LPS used in all the studies shown here was purified by phenol-chloroform-extraction 
45 and 
an anti-TLR2-blocking antibody had no effect in LPS signaling induced by LPS in any cell type 
(Figure 6).  The expression of TLR4 was also examined.  Using fluorescence-activated cell sorting 
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(FACS) analysis, TLR4 was detected at high levels in the surface of primary human macrophages. 
However, on SF and HUVEC TLR4 was undetectable (Figure 6D).
These data suggest that there are gross differences in LPS-induced NF-￿B activation and signaling 
in general between macrophages and non-myeloid cells such as SF and HUVEC. We investigated 
this further by analyzing the role of IKK2 as a kinase that has been deemed as essential for NF-￿B 
activation.  As  expected,  expression  of  IKK2dn  in  HUVEC  prevented  LPS-induced  NF-￿B 
activation (Figure 6E). However, this was not the case in macrophages where IKK2 had no effect 
in this process (Figure 6F).
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Fig. 6. Different requirements for TLR4 and IKK2 in LPS signaling in human macrophages 
and SF or HUVEC. Macrophages (A), SF (B) or HUVEC (C) were left untreated (white) or 
treated for 30 min with 10 µg/ml of TLR4 (black) or TLR2 (gray) neutralizing antibodies prior to 
addition of graded doses of chloroform-extracted LPS. After 20 h, supernatants were collected and 
assayed by ELISA for TNF￿ and IL-6. Mean cytokine production (±SD) of triplicate cultures is 
shown and is representative of five independent experiments for macrophages and three for SF and 
HUVEC. (D) SF, HUVEC and macrophages were analysed for the expression of TLR4 by FACS 
staining.  A  representative  of  three  independent  experiments  is  shown.  HUVEC  (E)  and 
macrophages  (F)  were  infected  with  adenoviruses  overexpressing  ￿-galactosidase,  IKK2dn  or 
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I￿B￿ for 2h in serum-free medium. Then cells were cultured in complete medium for another 1 day 
and  stimulated  1  µg/ml  and  10  ng/ml  LPS,  respectively.  After  45  min,  cytosolic  and  nuclear 
extracts were collected and assayed for I￿B￿ expression by W.B. and NF-￿B DNA binding by 
EMSA. A representative of three independent experiments from unrelated donors is shown.
Discussion
This  study  has  produced  the  novel  finding  that  there  are  unexpected  major  differences  in  the 
mechanisms of LPS-induced NF-￿B activation and cytokine production in primary cells of non-
myeloid and myeloid origin.  In SF and HUVEC, LPS signals via MyD88 or Mal/TIRAP and IKK2 
to induce NF-￿B activation and cytokine production through a pathway that cannot be shown to 
require TLR4.  In contrast, in primary human  macrophages LPS signals via TLR4 but neither 
MyD88  nor  Mal/TIRAP,  or  IKK2  appear  to  be  essential  for  NF-￿B  activation  and  cytokine 
production. These observations provide insight into the specificity of the adaptor molecules MyD88 
and Mal/TIRAP in LPS signaling and have important implications for therapeutic strategies aimed 
at inhibiting LPS activity.
The observation that LPS signals via TLR4, a TIR domain-containing receptor, suggested that LPS 
is actually using similar intracellular signaling mechanisms to these used by IL-1 receptor family 
members  which  also  contain  a  TIR  domain  in  their  cytoplasmic  region.  This  hypothesis  was 
initially supported by studies in a variety of cell lines that showed that LPS signals via MyD88, 
IRAK  and  TRAF6 
19,26,27,46.    However,  although  studies  with  MyD88
-/-  mice  confirmed  the 
importance of this adaptor to IL-1 receptor function 
24, they suggested that at least with respect to 
NF-￿B activation, MyD88 does not have a role in LPS signaling. Our observation that LPS-induced 
NF-￿B  activation  and  cytokine  production  can  occur  in  the  absence  of  MyD88  in  primary 
macrophages  disagrees  with  previous  studies  in  macrophage  cell  lines 
19,26,27  but  confirms  the 
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finding from MyD88
-/- mice that MyD88 is not required for NF-￿B activation. The failure to show a 
role for MyD88 in macrophages was not due to the approach of using an adenovirus delivery 
system  rather  than  transfection  because  adenoviral  infection  of  the  RAW  cell  line  with 
AdMyD88dn did inhibit LPS signaling, as expected from transfection studies. Also the MyD88dn 
was functional in primary macrophages as shown by the suppression of IL-1 signaling. Therefore 
the reason for the differences in the role of MyD88 between primary cells and cell lines may relate 
more to changes in signaling mechanisms induced by cell transformation.  There are antecedents for 
this as we and others have previously shown that pathways leading to NF-￿B activation are aberrant 
in cell lines, as was observed with NF-￿B-inducing kinase (NIK) that has a major role in LPS or 
cytokine-induced  NF-￿B  activation  in  cell  lines  but  not  primary  cells  where  it  appears  to  be 
important for LT￿R and BAFF-R signaling 
35,47-49. 
However, the differences between our data and MyD88
-/- mice are more difficult to understand. 
Thus, in addition to its lack of effect on NF-￿B activation, MyD88dn was also unable to block LPS-
induced  cytokine  production.  This  is  in  contrast  to  the  original  observation  that  MyD88
-/- 
macrophages do not produce cytokines in response to LPS.  Since LPS signaling to NF-￿B by the 
mutant macrophages is largely unaffected, the reason proposed for the loss of cytokine production 
was that this is due to a slight delay in the kinetics of activation of NF-￿B, although this hypothesis 
to our knowledge has not been confirmed, and indeed the recent study by Hoebe et al. published 
while this  manuscript  was  reviewed,  showed  that MyD88
-/-  macrophages  do  produce TNF￿  in 
response to LPS, albeit at lower levels 
50,51. This suggested that the discrepancy of our data with 
these  in  MyD88
-/-  macrophages  may  not  be  as  great  as  first  thought.    There  may  be  several 
explanations as to why the MyD88 and Mal/TIRAP role is different w.r.t. cytokine production 
between  our  system  and  the  knockout  mice.  First,  this  may  reflect  human  to  mouse  species 
differences as previously described in other cases such as SCID mice and human SCID patients 
52, 
xid mice and human XLA patients 
53. Second, our differences could relate to as yet undetected 
changes in macrophage development that result in a failure of LPS to induce cytokine expression. 
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Such a lesion would not be present in our studies where MyD88 activity is inhibited in already 
mature macrophages. Alternatively, differences may occur as a result of the expression of mutated 
or truncated versions of these proteins compared to their complete absence in mouse knockouts as 
for example with NIK 
34-36,48 . Finally, this may be due to “a second signal” provided for example 
by  M-CSF  or  recombinant  adenoviruses  used  that  bypasses  the  requirement  of  MyD88 and/or 
Mal/TIRAP  for  cytokine  production.  However,  M-CSF  has  also  been  used  to  generate  bone 
marrow-derived  macrophages  from  MyD88  and  Mal/TIRAP  deficient  mice 
43,44  and  adenoviral 
gene transfer into cells at a m.o.i. of 100 does not induce type I IFN production or activation of 
signaling  pathways  such  as  MAPKs,  PKR,  IRF3  (data  not  shown)  or  NF-￿B.  These  findings 
provide evidence against such a possibility although this cannot be unequivocally excluded. 
The absence of a role for MyD88 in LPS signaling in macrophages led to the study being extended 
to the more recently identified TIR-containing adaptor molecule, Mal/TIRAP. Initial studies mainly 
in  cell  lines  showed  that  this  molecule  was  a  potential  TLR4  specific  adaptor  molecule,  thus 
explaining the data from MyD88
-/- macrophages 
26,27. However, when we examined that in primary 
human  macrophages  we  found  that  the  mutated  versions  of  Mal/TIRAP  do  not  impair  LPS 
signaling. This does not appear to be due to an inability of Mal/TIRAP dominant negative to 
function, as it is still able to inhibit the production of IL-6 by macrophages induced by the simple 
overexpression of the wild-type protein. Our data are more in agreement with results obtained in 
macrophages from the very recently derived Mal/TIRAP
-/- mice. In these studies, Mal/TIRAP was 
shown to be involved in TLR1/2, TLR2/6 and TLR4 signaling 
43,44. LPS-induced NF-￿B activation 
was  unaffected  although  LPS-induced  TNF￿  production  from  Mal/TIRAP
-/-  macrophages  was 
abrogated in a similar manner to that seen with MyD88
-/- mice 
43,44. Again the differences between 
Mal/TIRAP
-/- and the early studies 
26,27 could be due to differences between cell lines and primary 
cells  as  discussed  above.    In  addition  to  the  studies  described  here  on  macrophages,  we  also 
examined  the role  of  MyD88  and Mal/TIRAP  in  LPS-induced  NF-￿B  activation  and  cytokine 
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production  in  another  primary  myeloid  cell  type,  human  immature  dendritic  cells  where  we 
obtained very similar results (manuscript in preparation). 
We also investigated the role of MyD88 and Mal/TIRAP in LPS signaling in primary non-myeloid 
cells such as SF and HUVEC that are also involved in the physiological response to endotoxin. We 
found that similarly to studies in cell lines, MyD88 is essential but Mal/TIRAP is not required for 
IL-1  signaling 
19,26,27.  This  was  in  contrast  to  the  response  to  LPS  where  both  MyD88  and 
Mal/TIRAP  were  needed  for  NF-￿B  activation  and  cytokine  production.  The  difference  in 
inhibitory  activity  of  Maldn  or  MyD88dn  in  the  different  cell  systems  could  not  be  trivially 
explained  by  the  concentration  of  LPS  used  or  the  expression  of  the  transgene.    An  obvious 
question that arises from the data is whether the roles of Mal/TIRAP and MyD88 in LPS signaling 
are totally redundant or display the existence of essential parallel pathways (Figure 7).  We believe 
that the latter is more likely since Mal/TIRAP, unlike MyD88, does not contain a DD and is 
therefore likely to engage alternative molecules to MyD88. This thesis is supported by the different 
nature  of  the  MyD88dn  and  Maldn  molecules  as  the  former  binds  to  the  TIR  domain  of  IL-
1R/TLRs but fails to engage distal signaling pathways due to the defective DD. In contrast Maldn 
has no functional TIR domain and presumably acts a sink for molecules that bind to the other 
regions of Mal/TIRAP. The observed lack of effect of Maldn on IL-1 signaling certainly provides 
further evidence for that as one would presume that this cytokine does not require the signaling 
pathways that Mal/TIRAP engages. It was interesting to note, however, that the overexpression of 
the  MalTIR  domain  did  block  IL-1  signaling,  an  observation  that  is  easily  explained  by  the 
saturation of the IL-1R TIR domain.  
Another  question  that  immediately  arises  is  what  pathways  are  mediated  by  Mal/TIRAP  as 
compared to MyD88.  The similar inhibitory effects of Mal/TIRAP and MyD88 dominant negative 
on  NF-￿B  activation  and  I￿B￿  degradation  in  non-myeloid  cells  suggests  the  convergence  of 
signaling  pathways  on  the  processes  of  I￿B￿  phosphorylation,  possibly  at  the  level  of  IKK2, 
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although  other  signaling  pathways  could  also  be  distal  of  Mal/TIRAP.  Another  possibility, 
suggested by Fitzgerald et al. 
26 is that MyD88 is part of the Mal/TIRAP pathway that still uses 
TRAF6 and IRAK1/2 that would more simply explain our data that both molecules lead to NF-￿B 
activation.  What pathways are triggered by Mal/TIRAP in primary human macrophages remain 
undefined but seem to involve IFN￿ production and probably expression of IFN￿-dependent genes 
as we have found that AdMaldn and AdMalTIR but not AdMyD88dn block LPS-induced IFN￿
mRNA expression as previously shown in the RAW cell line. However, the mechanism by which 
Maldn and MalTIR control the expression of IFN￿ in human macrophages is unclear as this is not 
due to an obvious role of Mal/TIRAP on IRF3 phosphorylation and activation (data not shown), in 
agreement with studies in Mal/TIRAP-deficient mice
43,44.  Previous studies have also shown that 
PKR  and  STAT1￿/￿  activation  as  well  as  IRF3  activation  and  IP-10  production  are  distal  of 
Mal/TIRAP 
27,  28,54.  In  our  studies,  however,  we  unable  to  observe  induction  of  PKR 
phosphosrylation  by  LPS  or  show  any  role  for  Mal/TIRAP  or  MyD88  on  LPS-induced  IP-10 
production in primary human macrophages (data not shown).
These data pose a further question as to why Maldn and MyD88dn fail to inhibit LPS signaling in 
macrophages but do so in other cells. One possibility is that there are other TIR adaptor molecules 
and  two  such  candidates,  TRIF/TICAM-1  and  TRAM/TICAM-2  were  described  while  this 
manuscript was under review 
55,56 57-59. The generation of TRIF/TICAM-1 deficient or mutant mice 
suggested a major role for this adaptor protein in LPS signaling 
50,51. LPS-stimulated macrophages 
from  these  mice  did  not  produce  cytokines,  and  did  not  activate  IRF3.  Interestingly,  NF-￿B 
activation in these cells in response to LPS was normal but completely abrogated when MyD88 and 
TRIF/TICAM-1 double deficient mice were generated. TRAM/TICAM-2 deficient macrophages 
had also a defect in NF-￿B activation but only at later timepoints 
57. If adaptor molecules such as 
TRIF/TICAM-1 and TRAM/TICAM-2 are expressed at higher levels in macrophages compared to 
other  cells,  it  is  possible  that  the  overexpressed  dominant  negative  forms  of  MyD88  and 
Mal/TIRAP fail to titrate these other adapters out. The other main possibility is that LPS uses 
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different receptors and/or signaling pathways in different cell types.  Since its discovery, TLR4 has 
been the major receptor believed to be involved in LPS signaling as well demonstrated in murine 
cells  of  the  myeloid  lineage 
7,60,61.  This  is  in  agreement  with  our  studies  in  primary  human 
macrophages showing that neutralizing TLR4 blocks LPS signaling. However, in contrast in SF and 
HUVEC, we were unable to show any role for TLR4 in LPS signaling as neutralizing TLR4 in
these  cells  had  no  effect.  This  correlated  with  the  lack  of  detectable  levels  of  surface  TLR4 
expression on HUVECs or SF whereas abundant levels could be detected in primary macrophages. 
Previous studies have suggested the presence of TLR4 in HUVEC, although this was shown by 
PCR and not by FACS 
62. Even then, the mRNA levels of TLR4 detected in HUVEC were found to 
be  very  much  lower  than  these found  in  myeloid  cells 
62. The  possibility  that  there  are  major 
differences in the signaling pathways used by LPS between cell systems is supported by the studies 
on IKK2 that appeared to be used only in SF and HUVECs (Figure 6, E-F, 
63,64). The data would 
suggest that in SF and HUVECs LPS signals by an unknown TLR via MyD88, Mal/TIRAP and 
IKK2 to activate NF-￿B and induce the expression of cytokines, although the possibility that TLR4 
is cryptic and cannot be blocked by the antibody still exists. In contrast, in macrophages LPS 
signals  via  TLR4  using  as  yet  unidentified  molecules  (Figure  7).  This  model  would  require 
Mal/TIRAP to act as an adaptor molecule for signaling through other TLRs distinct from TLR2 and 
TLR4. Indeed, we have evidence that Mal/TIRAP is also essential for the response to both TLR3 
(polyI:C)  and  TLR5  ligands  (flagellin)  in  HUVEC  (paper  in  preparation).  The  relationship  of 
MyD88 and IKK2 is further strengthened by our observation that IL-1 signaling to NF-￿B in SF, 
HUVECs  and  macrophages  always  uses  both  molecules 
64.  Interestingly,  in  human  immature 
dendritic cells where LPS signaling is also blocked by an anti-TLR4 neutralizing antibody (data not 
shown), IKK2 is not required for LPS-induced NF-￿B activation and cytokine production either 
63, 
further  supporting  significant  differences  in  LPS  signaling  between  human  myeloid  and  non-
myeloid cells. 
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Fig. 7. LPS uses a different framework of signaling molecules such as TLR4, MyD88, Mal and 
IKK2 to activate NF-￿ ￿￿￿B and induce NF-￿ ￿￿￿B-dependent cytokine production in human non-
myeloid (SF, HUVEC) and myeloid cells (macrophages, dendritic cells).
In summary, this study has shown major differences in the mechanisms used by LPS to activate 
primary  human  myeloid  and  non-myeloid  cells,  and  has  revealed  a  layer  of  complexity  not 
previously  expected.  As  LPS  is  a  major  pathogenic  factor  in  sepsis,  the  observation  that  the 
pathway  leading  to  NF-￿B  activation and  cytokine  production  in response  to  LPS  is  different 
between primary human myeloid and non-myeloid cells such as macrophages and endothelial cells 
may have important consequences when the development of therapeutics is being considered.
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